Combining a noble gas with radiotherapy: glutamate receptor antagonist xenon may act as a radiosensitizer in glioblastoma

Thomas Büttner,Marielena K. E. Maerevoet,Frank A. Giordano,Marlon R. Veldwijk,Carsten Herskind,Arne Mathias Ruder
DOI: https://doi.org/10.1186/s13014-023-02395-1
IF: 4.309
2024-02-01
Radiation Oncology
Abstract:Ionotropic glutamate receptors α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR) modulate proliferation, invasion and radioresistance in glioblastoma (GB). Pharmacological targeting is difficult as many in vitro-effective agents are not suitable for in patient applications. We aimed to develop a method to test the well tolerated AMPAR- and NMDAR-antagonist xenon gas as a radiosensitizer in GB.
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?